ADMA Biologics, Inc. (ADMA) EPS Estimated At $-0.35

July 14, 2018 - By Elizabeth Jones

ADMA Biologics, Inc. (NASDAQ:ADMA) LogoInvestors sentiment decreased to 2.86 in Q1 2018. Its down 0.14, from 3 in 2017Q4. It dropped, as 1 investors sold ADMA Biologics, Inc. shares while 6 reduced holdings. 11 funds opened positions while 9 raised stakes. 15.52 million shares or 0.06% less from 15.53 million shares in 2017Q4 were reported.
Barclays Public Limited Liability Co accumulated 2,901 shares. Sigma Planning owns 18,730 shares for 0.01% of their portfolio. Vanguard Gp invested in 886,987 shares. Broadfin Limited Liability Co invested 0.52% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA). Moreover, Highbridge Capital Limited Company has 0.02% invested in ADMA Biologics, Inc. (NASDAQ:ADMA). 12,890 are owned by Citadel Advsrs Lc. Bank & Trust Of America De reported 0% stake. Aisling Cap Limited Liability has invested 2.96% in ADMA Biologics, Inc. (NASDAQ:ADMA). Element Management Ltd Liability Corporation invested in 0% or 25,663 shares. Bank & Trust Of Ny Mellon accumulated 19,037 shares. Iguana Healthcare Mngmt Ltd Llc has invested 1.82% in ADMA Biologics, Inc. (NASDAQ:ADMA). Millennium Mngmt Lc invested in 0% or 273,621 shares. Morgan Stanley holds 0% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA) for 13,011 shares. Moreover, Prelude Cap Mngmt has 0.02% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 57,300 shares. Susquehanna Gp Llp invested in 0% or 94,476 shares.

Since June 8, 2018, it had 5 insider buys, and 0 insider sales for $744,504 activity. Another trade for 52,302 shares valued at $250,004 was bought by Grossman Jerrold B. Guiheen Lawrence P. bought 20,000 shares worth $95,600. $24,999 worth of ADMA Biologics, Inc. (NASDAQ:ADMA) shares were bought by RICHMAN ERIC I. $23,900 worth of ADMA Biologics, Inc. (NASDAQ:ADMA) was bought by LENZ BRIAN on Friday, June 8.

Analysts expect ADMA Biologics, Inc. (NASDAQ:ADMA) to report $-0.35 EPS on August, 10.They anticipate $0.20 EPS change or 36.36 % from last quarter’s $-0.55 EPS. After having $-0.35 EPS previously, ADMA Biologics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.09% or $0.14 during the last trading session, reaching $4.67. About 457,054 shares traded or 99.57% up from the average. ADMA Biologics, Inc. (NASDAQ:ADMA) has risen 49.86% since July 14, 2017 and is uptrending. It has outperformed by 37.29% the S&P500.

ADMA Biologics, Inc., a biopharmaceutical company, develops, makes, and markets specialty plasma biologics for the treatment of immune deficiencies and infectious diseases. The company has market cap of $210.59 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

More notable recent ADMA Biologics, Inc. (NASDAQ:ADMA) news were published by: Nasdaq.com which released: “ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes” on June 25, 2018, also Benzinga.com with their article: “30 Stocks Moving In Friday’s Mid-Day Session” published on July 13, 2018, Seekingalpha.com published: “ADMA Biologics: The Right Way To Fix Manufacturing” on June 14, 2018. More interesting news about ADMA Biologics, Inc. (NASDAQ:ADMA) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on July 13, 2018 as well as Seekingalpha.com‘s news article titled: “Rounds Report: Versartis Rallied Due To Strong Turnaround Progress” with publication date: June 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.